Exelume is the first treatment using photodisinfection to eradicate bacterial biofilms on the inner surface of endotracheal tubes, thus preventing the aspiration of pathogens in a mechanically ventilated patient.
The Exelume Advantage
Ondine believes that reducing the microbial load in ETT’s will result in reduced ventilator associated pneumonia (VAP) infection rate, less reliance on antibiotics (and resulting resistance generation) and reduced average length of hospital stay for intubated patients. These features are aimed to save lives while drastically lowering the costs of treatment.
Product Development Status
Exelume has undergone preclinical efficacy and toxicology testing, and several prototypes have been built in anticipation of an impending clinical trial.